Search

Your search keyword '"Rieux, C."' showing total 427 results
Start Over Author "Rieux, C."
427 results on '"Rieux, C."'

1. Caractéristiques cliniques et séquences thérapeutiques des patients atteints de cancer bronchique non à petites cellules (CBNPC) métastatique avec mutation KRAS G12C traités par sotorasib dans l’ATUc

Author

Quantin, X., primary, Cadranel, J., additional, Girard, N., additional, Mazières, J., additional, Curcio, H., additional, Gille, R., additional, Madroszyk, A., additional, Auliac, JB., additional, Bylicki, O., additional, Rieux, C., additional, Couraud, S., additional, Barlesi, F., additional, Pichon, E., additional, Métivier, AC., additional, Almotlak, H., additional, Pabst, L., additional, Deldycke, C., additional, Duchemann, B., additional, De Gunten, L., additional, and Léna, H., additional

Published
2024
Full Text
View/download PDF

5. Premières données de vraie vie des patients (pts) atteints d’un cancer bronchique non à petites cellules métastatique (CBNPCm) muté KRAS au sein du programme français d’autorisation temporaire d’utilisation (ATU) : caractéristiques cliniques de 679 pts à l’initiation du traitement

Author

Léna, H., primary, Quantin, X., additional, Girard, N., additional, Barlesi, F., additional, Auliac, J.B., additional, Couraud, S., additional, Madroszyk Flandin, A.C., additional, Pabst, L., additional, Rieux, C., additional, Curcio, H., additional, Gille, R., additional, Métivier, A.C., additional, Becht, C., additional, Bylicki, O., additional, Tomasini, P., additional, Veillon, R., additional, Damade, C., additional, Mourad, C., additional, Veillard, C., additional, and Cadranel, J., additional

Published
2023
Full Text
View/download PDF

7. 1121P Real-world (RW) data from the sotorasib French pre-market authorization early access program in patients (pts) with KRASG12C driven metastatic non-small cell lung cancer (mNSCLC): Clinical characteristics

Author

Cadranel, J., primary, Quantin, X., additional, Girard, N., additional, Barlesi, F., additional, Auliac, J.B., additional, Couraud, S., additional, Madroszyk Flandin, A-C., additional, Pabst, L., additional, Rieux, C., additional, Curcio, H., additional, Gille, R., additional, Métivier, A-C., additional, Becht, C., additional, Bylicki, O., additional, Tomasini, P., additional, Veillon, R., additional, Damade, C., additional, Mourad, C., additional, Veillard, C., additional, and Lena, H., additional

Published
2022
Full Text
View/download PDF

9. 728 Médecins sans frontières cervical cancer (CC) project in malawi: results of a neoadjuvant chemotherapy (NACT) strategy for locally advanced CC

Author

Chilinda, G, primary, Husein, F, additional, Massamba, L, additional, Meja, S, additional, Gadama, L, additional, Gadama, G, additional, Sylvie, G, additional, Danielyan, N, additional, Curry, N, additional, Bah, OP, additional, Mambula, C, additional, Rieux, C, additional, Ngo, C, additional, and Dupre, PF, additional

Published
2021
Full Text
View/download PDF

10. 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)

Author

Lena, H., Cadranel, J., Girard, N., Mazieres, J., Curcio, H., Gille, R., Madroszyk Flandin, A-C., Auliac, J.B., Bylicki, O., Rieux, C., Couraud, S., Barlesi, F., Pichon, E., Métivier, A-C., Almotlak, H., Pabst, L., Deldycke, C., Duchemann, B., De Gunten, L., and Quantin, X.

Published
2023
Full Text
View/download PDF

12. LBA69 Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients

Author

Joly, F., primary, Leconte, A., additional, Grellard, J-M., additional, Lequesne, J., additional, Binarelli, G., additional, Lange, M., additional, Tron, L., additional, Gernier, F., additional, Rieux, C., additional, Fernette, M., additional, Bastien, E., additional, Morel, A., additional, Legrand, B., additional, Richard, D., additional, Faveyrial, A., additional, Travers, R., additional, Pépin, L-F., additional, Rigal, O., additional, Jardin, F., additional, and Clarisse, B., additional

Published
2020
Full Text
View/download PDF

14. TRALI: FRANCE MAKES UP FOR ITS LOST TIME: P-640

Author

Rebibo, D. R., Hauser, L. H., Muller, J. Y.M., Dorne, R. D., Ducroz, F. D., Fontaine, O. F., Lee, K., Merillon, M. C.M., Meyer, F. M., Odent-Malaure, H. O.M., Ounnoughene, N., Rieux, C. R., Slimani, A. S., Tazerout, M., and Andreu, G. A.

Published
2006

19. Small-molecule inhibitors of Fpg/Nei DNA glycosylases, enzymes initiating the base excision repair pathway, new targets for cancer therapy

Author

Rieux, C., Coste, F., Culard, F., Goffinont, S., Bourg, S., Roy, V., Agrofoglio, L., Castaing, Bertrand, Garnier, Norbert, Centre de biophysique moléculaire (CBM), Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut de Chimie Organique et Analytique (ICOA), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Université d'Orléans (UO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), and Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

21. Impact of art therapy (AT) on fatigue and quality of life (QoL) during adjuvant external beam irradiation (EBI) in breast cancer patients (pts): a randomized trial

Author

Joly, F., primary, Pasquier, D., additional, Hanzen, C., additional, Heutte, N., additional, Levy, C., additional, Le Tinier, F., additional, Mousseau, M., additional, Ciais, C., additional, Murariu, C., additional, D'almeida, M.-C., additional, Szymczak, V., additional, Leon, C., additional, Darbas, S., additional, Rousselot, M.-P., additional, Mineur, S., additional, Rieux, C., additional, Leconte, A., additional, Rigal, O., additional, Clarisse, B., additional, and Allouache, D., additional

Published
2016
Full Text
View/download PDF

23. Hémolyse post-transfusionnelle retardée chez des patients drépanocytaires adultes ; caractéristiques, évolutions et traitements de 99 épisodes

Author

Habibi, A., primary, Mekontso-Dessap, A., additional, Guillaud, C., additional, Michel, M., additional, Razazi, K., additional, Khellaf, M., additional, Chami, B., additional, Rieux, C., additional, Godeau, B., additional, Galactéros, F., additional, Bartolucci, P., additional, and Pirenne, F., additional

Published
2016
Full Text
View/download PDF

28. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients

Author

Karim Belhadj, P. Gaulard, P. Morel, Felix Reyes, Christian Gisselbrecht, Corinne Haioun, Rieux C, Bruno Quesnel, D. Simon, Eric Lepage, Nicolas Mounier, Jean-Pierre Marolleau, and F. Beaujean

Subjects
Oncology, Melphalan, Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Cyclophosphamide, Adolescent, Vindesine, medicine.medical_treatment, T-Lymphocytes, Aggressive lymphoma, Pilot Projects, Hematopoietic stem cell transplantation, Transplantation, Autologous, Bleomycin, International Prognostic Index, Risk Factors, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Neoplasm Staging, Chemotherapy, business.industry, Palliative Care, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, Prognosis, Surgery, Transplantation, Survival Rate, Treatment Outcome, Doxorubicin, Prednisone, Female, Lymphoma, Large B-Cell, Diffuse, business, Busulfan, medicine.drug
Abstract

Summary Purpose In the previous LNH87-2 study, consolidative high-dose therapy followed by stem cell transplantation (HDT) improved disease-free survival, as well as survival for patients (pts) presenting with two or three factors of the age-adjusted international prognostic index (Aa-IPI) in first complete remission (CR). In order to improve further the outcome of such patients, we conducted a pilot study of consolidative tandem autotranplant. Patients and methods Thirty-six patients (pts) under 60 years of age with two or three factors of the Aa-IPI were enrolled. Their main characteristics were: diffuse large B-cell lymphoma (830025), Aa-IPI three factors (500025), and marrow involved (36)0025. The procedure consisted of 1) induction with four cycles of ACVBP (doxorubicin, cyclophosphamide, vin-desine, bleomycin, prednisone) 2) in responding pts, peripheral blood stem cell (PBSC) collection after the fourth cycle of ACVBP (11 pts) or after an additional mobilization regimen (Cyclophosphamide - VP16) (17 pts) 3) a first HDT (mitoxan-trone, cyclophosphamide, VP16 and carmustine) followed by PBSC infusion 4) a second HDT (busulfan, carboplatin and melphalan) followed by PBSC infusion. Among the 29 patients responding to induction, 28 received the first HDT and 24 the second. Results The rates of three-year-event free survival and survival are 470025 (950025 confidence interval (950025 Cl: 310025630025) and 500025 (950025 Cl: 370025–690025), respectively. Eighteen patients remained free of evolutive disease and 18 patients have died, 15 from disease progression and three from treatment-related toxicity after tandem transplant (two veno-occlu-sive disease and one cerebral toxoplasmosis). Conclusion We conclude that tandem transplant did not improve the results of the LNH87-2 study in which patients received a single consolidative HDT.

Published
2002

31. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial.

Author

Heutte, N., Flechtner, H.H., Mounier, N., Mellink, W.A.M., Meerwaldt, J.H., Eghbali, H., Veer, M.B. van 't, Noordijk, E.M., Kluin-Nelemans, H.C., Lampka, E., Thomas, J., Lugtenburg, P.J., Viterbo, L., Carde, P., Hagenbeek, A., Maazen, R.W.M. van der, Smit, W.G., Brice, P., Marwijk-Kooy, M. van, Baars, J.W., Poortmans, P.M.P., Tirelli, U., Leeksma, O.C., Tomsic, R., Feugier, P., Salles, G., Gabarre, J., Kersten, M.J., Neste, E. van den, Creemers, G.J., Gaillard, I., Meijnders, P., Tertian, G., Reman, O., Muller, H.P., Troncy, J., Blanc, M., Schroyens, W., Voogt, P.J., Wijermans, P., Rieux, C., Ferme, C., Henry-Amar, M., Heutte, N., Flechtner, H.H., Mounier, N., Mellink, W.A.M., Meerwaldt, J.H., Eghbali, H., Veer, M.B. van 't, Noordijk, E.M., Kluin-Nelemans, H.C., Lampka, E., Thomas, J., Lugtenburg, P.J., Viterbo, L., Carde, P., Hagenbeek, A., Maazen, R.W.M. van der, Smit, W.G., Brice, P., Marwijk-Kooy, M. van, Baars, J.W., Poortmans, P.M.P., Tirelli, U., Leeksma, O.C., Tomsic, R., Feugier, P., Salles, G., Gabarre, J., Kersten, M.J., Neste, E. van den, Creemers, G.J., Gaillard, I., Meijnders, P., Tertian, G., Reman, O., Muller, H.P., Troncy, J., Blanc, M., Schroyens, W., Voogt, P.J., Wijermans, P., Rieux, C., Ferme, C., and Henry-Amar, M.

Abstract

Contains fulltext : 81805.pdf (publisher's version ) (Closed access), BACKGROUND: Little is known about the longitudinal course of health-related quality of life (HRQoL) in patients with Hodgkin's lymphoma during their post-treatment follow-up and re-adaptation to normal life. We report on the HRQoL of patients treated in the randomised H8 trial of the European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). We aimed to assess HRQoL and fatigue following treatment, to analyse relations with treatment, and to identify factors that predict persistent fatigue. METHODS: Patients received HRQoL questionnaires at the end of primary therapy and during follow-up. The EORTC QLQ-C30 was used to assess HRQoL, and the Multidimensional Fatigue Inventory (MFI-20) was used to assess fatigue. Changes of mean HRQoL scores over time were analysed with mixed models. Multiple polytomic nominal logistic regression was done to identify independent baseline predictors of fatigue within MFI-20 dimensions. Analyses were done on an intention-to-treat basis. This study is registered with www.ClinicalTrials.gov, number NCT00379041. FINDINGS: 2666 assessments from 935 patients were analysed. Mean follow-up was 90 months (range 52-118). Age affected all functioning and symptom scores except emotional functioning, with younger age associated with higher functioning and lower severity of symptoms; improvement with time showed similar patterns between age groups. Women reported lower HRQoL and higher symptom scores than did men. Overall, 3.2% (14/439 for role functioning) to 9.7% (43/442 for social functioning) and 5.8% (29/498 for reduced motivation) to 9.9% (49/498 for general fatigue) of patients reported impairments of 10 points or more (on a 0-100 scale) in QLQ-C30 and MFI-20 scores, respectively, independent of age and sex. Emotional domains were more affected than physical ones. There was no relation between HRQoL outcome and type of treatment. Fatigue (MFI-20 scores) at the end

Published
2009

34. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.

Author

Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., Veer, M.B. van 't, Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Neste, E. van den, Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P.M.P., Lugtenburg, P., Carrie, C., Jaubert, J., Henry-Amar, M., Ferme, C., Eghbali, H., Meerwaldt, J.H., Rieux, C., Bosq, J., Berger, F., Girinsky, T., Brice, P., Veer, M.B. van 't, Walewski, J.A., Lederlin, P., Tirelli, U., Carde, P., Neste, E. van den, Gyan, E., Monconduit, M., Divine, M., Raemaekers, J.M.M., Salles, G., Noordijk, E.M., Creemers, G.J., Gabarre, J., Hagenbeek, A., Reman, O., Blanc, M., Thomas, J., Vie, B., Kluin-Nelemans, J.C., Viseu, F., Baars, J.W., Poortmans, P.M.P., Lugtenburg, P., Carrie, C., Jaubert, J., and Henry-Amar, M.

Abstract

Item does not contain fulltext, BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year event-free survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P=0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (Clin

Published
2007

35. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease

Author

Fermé, C. (Christophe), Eghbali, H. (Houchingue), Meerwaldt, J.H. (Jacobus), Rieux, C. (Chantal), Bosq, J. (Jacques), Berger, F. (Françoise), Girinsky, T. (Théodore), Brice, P. (Pauline), Veer, M.B. (Mars) van 't, Walewski, J. (Jan), Lederlin, P. (Pierre), Tirelli, U. (Umberto), Carde, P. (Patrice), Neste, E. (Eric) van den, Gyan, E. (Emmanuel), Monconduit, M. (Mathieu), Diviné, M. (Marine), Raemaekers, J. (John), Salles, G. (Gilles), Noordijk, E.M. (Evert), Creemers, G.J.M. (Geert-Jan), Gabarre, J. (Jean), Hagenbeek, A. (Anton), Reman, O. (Oumédaly), Blanc, M. (Michel), Thomas, J. (Jose), Vié, B. (Brigitte), Kluin-Nelemans, J.C. (Hanneke), Viseu, F. (Fernando), Baars, J.W. (Joke), Poortmans, P.M.P. (Philip), Lugtenburg, P.J. (Pieternella), Carrie, C. (Christian), Jaubert, J. (Jérôme), Henry-Amar, M. (Michel), Fermé, C. (Christophe), Eghbali, H. (Houchingue), Meerwaldt, J.H. (Jacobus), Rieux, C. (Chantal), Bosq, J. (Jacques), Berger, F. (Françoise), Girinsky, T. (Théodore), Brice, P. (Pauline), Veer, M.B. (Mars) van 't, Walewski, J. (Jan), Lederlin, P. (Pierre), Tirelli, U. (Umberto), Carde, P. (Patrice), Neste, E. (Eric) van den, Gyan, E. (Emmanuel), Monconduit, M. (Mathieu), Diviné, M. (Marine), Raemaekers, J. (John), Salles, G. (Gilles), Noordijk, E.M. (Evert), Creemers, G.J.M. (Geert-Jan), Gabarre, J. (Jean), Hagenbeek, A. (Anton), Reman, O. (Oumédaly), Blanc, M. (Michel), Thomas, J. (Jose), Vié, B. (Brigitte), Kluin-Nelemans, J.C. (Hanneke), Viseu, F. (Fernando), Baars, J.W. (Joke), Poortmans, P.M.P. (Philip), Lugtenburg, P.J. (Pieternella), Carrie, C. (Christian), Jaubert, J. (Jérôme), and Henry-Amar, M. (Michel)

Abstract

BACKGROUND: Treatment of early-stage Hodgkin's disease is usually tailored in line with prognostic factors that allow for reductions in the amount of chemotherapy and extent of radiotherapy required for a possible cure. METHODS: From 1993 to 1999, we identified 1538 patients (age, 15 to 70 years) who had untreated stage I or II supradiaphragmatic Hodgkin's disease with favorable prognostic features (the H8-F trial) or unfavorable features (the H8-U trial). In the H8-F trial, we compared three cycles of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) combined with doxorubicin, bleomycin, and vinblastine (ABV) plus involved-field radiotherapy with subtotal nodal radiotherapy alone (reference group). In the H8-U trial, we compared three regimens: six cycles of MOPP-ABV plus involved-field radiotherapy (reference group), four cycles of MOPP-ABV plus involved-field radiotherapy, and four cycles of MOPP-ABV plus subtotal nodal radiotherapy. RESULTS: The median follow-up was 92 months. In the H8-F trial, the estimated 5-year eventfree survival rate was significantly higher after three cycles of MOPP-ABV plus involved-field radiotherapy than after subtotal nodal radiotherapy alone (98% vs. 74%, P<0.001). The 10-year overall survival estimates were 97% and 92%, respectively (P = 0.001). In the H8-U trial, the estimated 5-year event-free survival rates were similar in the three treatment groups: 84% after six cycles of MOPP-ABV plus involved-field radiotherapy, 88% after four cycles of MOPP-ABV plus involved-field radiotherapy, and 87% after four cycles of MOPP-ABV plus subtotal nodal radiotherapy. The 10-year overall survival estimates were 88%, 85%, and 84%, respectively. CONCLUSIONS: Chemotherapy plus involved-field radiotherapy should be the standard treatment for Hodgkin's disease with favorable prognostic features. In patients with unfavorable features, four courses of chemotherapy plus involved-field radiotherapy should be the standard treatment. (Cli

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results